

Please amend the above-identified application as set forth below.

**IN THE SPECIFICATION**

Please insert following paragraph between "The Title of the Invention" and "BACKGROUND OF THE INVENTION"

**--CROSS-REFERENCE TO RELATED APPLICATIONS**

B1

This application is a continuation-in-part of U.S. application Serial No. 09/993,003 filed on November 6, 2001, which is currently pending.--

**REMARKS**

Claims 1-37 are currently pending in the present application.

The specification has been amended to insert a reference to the parent application in order to comply with the requirements of 35 U.S.C. §120 for claiming the benefit of an earlier-filed U.S. patent application.

**The Restriction Requirement**

In response to the Office Action dated July 2, 2002, and the restriction requirement made in the Office Action dated April 23, 2002, Applicant provisionally elects Group I, claims 1-20, for initial examination on the merits with traverse.

1-20

In support of the restriction requirement, the Examiner alleges that the process as claimed in claims 1-2 can be practiced with another materially different product, alleging that interleukin-1- $\alpha$  derivatives can be used in the method claimed in claims 1-20. The applicant traverses the requirement on the basis that claims 1-20 specifically require the use of the composition of claims 21-37 in the method of claims 1-20. Accordingly, interleukin-1- $\alpha$  derivatives cannot be used in the process, as claimed, since the process, as claimed, requires the use of the composition of claims 21-37.